Navigation Links
Dyadic International Reports Profitable 2012 Full Year Financial Results
Date:3/7/2013

JUPITER, Fla., March 7, 2013 /PRNewswire/ -- Dyadic International, Inc. (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and others proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries, today announced financial results for the year ended December 31, 2012.

(Logo:  http://photos.prnewswire.com/prnh/20110621/CL06708LOGO)

Full Year 2012 Financial Highlights

  • Total Revenue increased 52%
  • License Fee Revenue increased 441%
  • Research and Development Revenue increased 25%
  • Product Related Revenue increased 6%
  • Gross Profit increased 121%
  • Total Expenses decreased 18%
  • Income from Operations of $1.6 million compared to a loss of $4.2 million in the prior year
  • Net Income of $1.3 million compared to a Net Loss of $4.7 million in the prior year
  • Full Year 2012 Operational Highlights

  • Licensing
  • Expanded license agreement with Abengoa New Technologies, Inc. ("Abengoa Bioenergy") for $5.5 million plus potential royalties and facility fees
  • Entered into a research, development and license agreement to use Dyadic's C1 platform technology to develop and produce enzymes for food applications
  • Research and Development
  • Demonstrated AlternaFuel® CMAX™ enzymes equal or exceed other industry-leading enzymes in converting biomass into fermentable sugars for the production of biofuels and bio-based chemicals
  • Successful verification of Dyadic's biofuels enzymes by SEKAB E-Technology in the ethanol demonstration plant in Sweden
  • Extended existing research projects funded by third parties in the areas of animal health and nutrition, food and biopharmaceuticals
  • Joined the Bio-Mimetic Project and the HealthBread Project, two multidisciplinary research consortia funded by the European Community's Seventh Framework Programme (FP7)
  • New Products
  • Launched FibreZyme® G5000 high performance powder enzyme for pulp and paper manufacturing processes
  • Patents
  • Received four new issued patents (two U.S. and two foreign)
  • Dyadic's President and Chief Executive Officer, Mark Emalfarb, stated, "We executed our strategy very effectively in 2012, resulting in our first yearly profit since 2009. By demonstrating the capabilities of our technologies and products to our licensees, research partners and customers, we increased revenue in every business segment. Because our C1 platform creates real value in diverse applications such as animal health and nutrition, food, biofuels and biopharmaceuticals, we believe our efforts to identify new collaborations and sales will bear fruit in the months and years ahead. Provided we conclude a specific pending licensing transaction, 2013 is anticipated to be another great year that should equal or exceed our 2012 results."

    Full Year 2012 Financial ResultsRevenue. Total revenue increased 52% for the year ended December 31, 2012 to $15.6 million as compared to $10.3 million for the prior year.

    License fee revenue increased more than fivefold to $5.5 million for the year ended December 31, 2012 as compared to $1.0 million for the prior year. This increase was due to a $5.5 million license fee recognized in the second quarter of 2012 from Dyadic's non-exclusive licensee, Abengoa Bioenergy, for an expansion of its rights under its license agreement with Dyadic.

    Research and development revenue increased 25% to $2.3 million for the year ended December 31, 2012 as compared to $1.8 million for the year ended December 31, 2011.

    Net product related revenue increased 6% to $7.8 million for the year ended December 31, 2012 as compared to $7.4 million for the prior year.

    Gross Profit. Gross profit increased 121% to $8.0 million for the year ended December 31, 2012 as compared to $3.6 million for the prior year primarily due to the contribution from license fee revenue, which has very high margins.

    Expenses. Total expenses decreased 18% to $6.4 million for the year ended December 31, 2012 as compared to $7.8 million for the prior year, due largely to a reduction in litigation-related costs, as well as Dyadic's focus on improving cost controls and operational efficiencies.

    Settlement of Litigation. In August 2012, Dyadic received $525,000 for the settlement of certain of its claims against two defendants in Dyadic's professional liability lawsuit against its former outside legal counsel. The settlement is included in Other Income (Expense) for the year ended December 31, 2012.

    Net Income. Net income for the year ended December 31, 2012 was $1.3 million, or $0.04 per basic and fully diluted share, as compared to a net loss of $4.7 million, or ($0.15) per basic and fully diluted share, for fiscal 2011.

    Cash and Cash Equivalents. At December 31, 2012, cash and cash equivalents totaled $4.0 million as compared to $3.7 million at December 31, 2011. The increase was partially due to Dyadic's receipt of the first $2.0 million of the total license fee of $5.5 million for the expansion of Dyadic's license with Abengoa Bioenergy in April 2012.

    Debt. At December 31, 2012, total debt was $8.4 million which was unchanged from December 31, 2011.

    The financial information contained in this press release should be read in conjunction with the financial statements and related footnotes which have been posted on the OTC market website at http://www.otcmarkets.com/stock/DYAI/filings and on Dyadic's website at http://dyadic.com/investorinfo/financials/.

    Conference CallDyadic's 2012 year-end financial results conference call is scheduled for 5:00 p.m. Eastern Time on Thursday, March 7, 2013. The conference call may be accessed by dialing 888-259-8885 (from the United States or Canada) or 913-312-0695 (from other countries) five to ten minutes prior to start time and providing the passcode 1207134. A replay of the conference call will be available on the Dyadic website (www.dyadic.com) shortly after the live event.

    About DyadicDyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries.

    Dyadic trades on the OTC Pink tier of the OTC market. Investors can find real-time quotes, market information and financial reports for Dyadic on the OTC market website (www.otcmarkets.com/stock/DYAI/quote).

    Cautionary Statement for Forward-Looking StatementsCertain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.

     DYADIC INTERNATIONAL, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF OPERATIONSYear Ended December 31, 20122011Revenue:Product Related Revenue, Net

    $

    7,819,547

    $

    7,407,908License Fee Revenue5,500,0001,017,000Research and Development Revenue2,282,1731,825,304Total Revenue15,601,72010,250,212Cost of Goods Sold7,616,2226,641,666Gross Profit7,985,4983,608,546Expenses:General and Administrative4,802,6535,649,028Sales and Marketing 700,7781,112,213Research and Development 921,7141,047,478Foreign Currency Exchange (Gains)/Losses, Net(27,989)38,144Total Expenses6,397,1567,846,863Income (Loss) from Operations1,588,342(4,238,317)Other Income (Expense) Interest Income5,24510,789Interest Expense(701,090)(517,742)Gain on Settlement of Litigation525,000-Other-1,709Total Other Income (Expense)(170,845)(505,244)Income (Loss) before Provision for Income Taxes1,417,497(4,743,561)Provision for Income Taxes(68,000)-Net Income (Loss)

    $

    1,349,497

    $

    (4,743,561)Net Income (Loss) per Common Share:Basic

    $

    0.04

    $

    (0.15)Diluted

    $

    0.04

    $

    (0.15)Weighted Average Common Shares Used in Calculating Net Income (Loss) per Share:Basic31,608,84131,349,980Diluted34,225,59031,349,980 DYADIC INTERNATIONAL, INC. AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETSDecember 31,20122011ASSETSCurrent Assets:Cash and Cash Equivalents$

    3,990,062

    $

    3,691,755Restricted Cash192,355214,376Accounts Receivable, Net1,260,7981,774,773License Fee Receivable3,500,000-Inventory, Net2,765,1873,276,382Prepaid Expenses and Other Current Assets237,389280,812Total Current Assets11,945,7919,238,098Fixed Assets, Net393,860552,221Intangible Assets, Net525,224497,385Other Assets16,17316,173$

    12,881,048

    $

    10,303,877LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)Current Liabilities:Accounts Payable$

    1,687,177

    $

    2,035,253Accrued Expenses412,483439,040Accrued Interest Payable1,905173,496Note Payable to Stockholder1,424,9411,424,941Deferred Research and Development Obligation567,40029,134Total Current Liabilities4,093,9064,101,864Convertible Subordinated Debt7,000,0007,000,000Total Liabilities11,093,90611,101,864COMMITMENTS AND CONTINGENCIESStockholders' Equity (Deficit):Preferred Stock, $.0001 Par Value:Authorized Shares – 5,000,000; None Issued and Outstanding--Common Stock, $.001 Par Value,Authorized Shares – 100,000,000; Issued and Outstanding – 31,656,245 and 31,448,745, Respectively31,65631,449Additional Paid-In Capital79,847,76178,608,586Stock to be Issued-3,750Accumulated Deficit(78,092,275)(79,441,772)Total Stockholders' Equity (Deficit)1,787,142(797,987)$

    12,881,048

    $

    10,303,877 DYADIC INTERNATIONAL, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF CASH FLOWSYear Ended December 31,20122011Operating ActivitiesNet Income (Loss)1,349,497(4,743,561)Adjustments to Reconcile Net Income (Loss) to Net Cash  Provided By (Used In) Operating Activities:Depreciation and Amortization of Fixed Assets204,176247,350Amortization of Intangible and Other Assets52,30537,773Increase (Decrease) in Allowance for Doubtful Accounts320,573(61,968)Increase (Decrease) in Inventory Reserve245,000(75,389)Compensation Expense on Stock Option Grants1,198,5591,454,214Change in Operating Assets and LiabilitiesAccounts Receivable193,402(436,231)License Fee Receivable(3,500,000)-Inventory266,195(418,560)Prepaid Expenses and Other Current Assets43,42355,826Other Assets-757Accounts Payable(348,076)264,585Accrued Expenses(26,557)19,723Accrued Interest Payable(171,591)27,266Deferred Research and Development Obligation538,266-Income Taxes Payable-(168)Net Cash Provided by (Used In) Operating Activities365,172(3,628,383)Investing ActivitiesPurchases of Fixed Assets(45,815)(80,410)Patent Costs(80,144)(224,180)Restricted Cash22,02132,706Net Cash (Used In) Investing Activities(103,938)(271,884)Financing ActivitiesProceeds from Issuance of Convertible Subordinated Debt-3,000,000Proceeds from Stock Warrant Exercises-15,000Proceeds from Stock Option Exercises37,07341,743Net Cash Provided by Financing Activities37,0733,056,743Net Increase (Decrease) in Cash and Cash Equivalent298,307(843,524)Cash and Cash Equivalents at Beginning of Year3,691,7554,535,279Cash and Cash Equivalents at End of Year$

    3,990,062

    $

    3,691,755Supplement Cash Flow Information:Cash Paid:Interest$

    872,681

    $

    490,477Income Taxes$

    68,000

    $

    -
    '/>"/>

    SOURCE Dyadic International, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Dyadic Netherlands To Develop Enzymes For EU-Funded Research Consortium
    2. Dyadic International To Announce Third Quarter 2012 Financial Results And Host Conference Call On Thursday, November 8, 2012
    3. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
    4. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
    5. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
    6. SurgLine International, Inc. Launches A Wholly Owned Operating Subsidiary To Pursue Cost Containment Strategies
    7. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
    8. Chindex International, Inc. to Report First Quarter 2012 Financial Results
    9. VWR International, LLC Signs Agreement to Acquire basan Germany GmbH
    10. Pharmaceutics International, Inc. (Pii) Supports University Pharmaceutical Technology Education and Research
    11. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/5/2016)... 2016  Aralez Pharmaceuticals Inc. ("Aralez") today announced the ... Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval of the ... The combined company will operate under Aralez Pharmaceuticals Inc. ... Canada , Ireland ... Under the terms of the Agreement and Plan of ...
    (Date:2/5/2016)... , Feb. 5, 2016  Venice,s newest laser ... the first of its kind in the area ... through advanced laser treatment. The physician-owned and operated ... Suncoast by storm with its revitalizing skin ... advanced multi-wavelength Astanza Trinity technology. http://photos.prnewswire.com/prnh/20160204/329957 ...
    (Date:2/5/2016)... , Feb. 5, 2016  Zimmer Biomet Holdings, Inc. ... the previously announced underwritten secondary offering of 11,027,558 shares ... consisting of affiliates of Blackstone and Goldman Sachs.  The ... initial price of $96.45 per share. The selling stockholders ...  Neither Zimmer Biomet nor any of its directors, officers ...
    Breaking Medicine Technology:
    (Date:2/6/2016)... St. Petersburg, FL (PRWEB) , ... February 06, 2016 , ... ... AsSeenOnTV.pro are pleased to announce the launch of a new DRTV campaign with Belly ... rug. If having tried everything from sprays to puppy pads and find nothing works, ...
    (Date:2/5/2016)... ... February 05, 2016 , ... Love is in the ... a variety of colors, assortments and packaging. This staple for Valentine’s Day is a ... location. , For Valentine’s Day, not only are long-stem roses available, but also ...
    (Date:2/5/2016)... ... 05, 2016 , ... Successful recruitment and retention efforts, new ... initiatives have all marked the last 12 months at Roswell Park Cancer Institute ... nation’s oldest cancer center, Candace S. Johnson, PhD, outlined the many accomplishments of ...
    (Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... announce the addition of micro-needling services in their Napa Valley office. The technique ... of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part of only ...
    (Date:2/5/2016)... Toronto, Ontario (PRWEB) , ... February 05, 2016 , ... ... the Scarborough General Hospital Burn Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned ... the Scarborough Hospital. He successfully completed his first three-year term as chief and began ...
    Breaking Medicine News(10 mins):